Education
About Us
Working with TipRanks
Follow Us
Alumis Inc. (ALMS)
NASDAQ:ALMS
ALMS Stock Chart & Stats
$29.72
-$0.47(-5.84%)
At close: 4:00 PM EST
$29.72
-$0.47(-5.84%)
Day’s Range― - ―
52-Week Range$2.76 - $30.60
Previous CloseN/A
Volume29.29K
Average Volume (3M)1.44M
Market Cap
$3.71B
Enterprise Value$3.07B
Total Cash (Recent Filing)$377.72M
Total Debt (Recent Filing)$37.80M
Price to Earnings (P/E)―
Beta-1.76
Next Earnings
Mar 25, 2026EPS Estimate
-0.98Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.06
Shares Outstanding117,506,000
10 Day Avg. Volume1,281,844
30 Day Avg. Volume1,438,777
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.86
Price to Sales (P/S)0.00
P/FCF Ratio-0.87
Enterprise Value/Market Cap0.83
Enterprise Value/Revenue138.88
Enterprise Value/Gross Profit144.23
Enterprise Value/Ebitda-7.24
Forecast
1Y Price Target
$38.38Price Target Upside29.14% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-3.06
Revenue Forecast (FY)$6.99M
Bulls Say, Bears Say
Bulls Say
Phase 3 Clinical EfficacyPhase 3 trials met co-primary and secondary endpoints, showing deeper and faster skin clearance versus placebo and some oral competitors, a profile that could shift prescribing toward the drug.
Pipeline Expansion And Strategic OptionalityPositive psoriasis data strengthen the case for pursuing systemic lupus and other autoimmune indications and increase attractiveness for commercial partnerships to support launch and growth.
Safety And TolerabilitySafety findings were consistent with earlier studies, with no new safety signals and mostly mild-to-moderate adverse events, lowering approval and regulatory risk.
Bears Say
Comparability And Measurement UncertaintyDiffering measurement timepoints and sparse topline detail make direct comparisons with other programs uncertain, complicating clear positioning against competitors.
Competitive LandscapeThe program faces strong competition from established biologic therapies and long-acting injectables, which could limit market share unless clear advantages are demonstrated.
Data Transparency ConcernsLimited disclosure of full trial data raises questions about the durability of deep responses, trial-to-trial consistency, and methods for handling missing data, which could weigh on investor confidence.
Alumis Inc. News
ALMS FAQ
What was Alumis Inc.’s price range in the past 12 months?
Alumis Inc. lowest stock price was $2.76 and its highest was $30.60 in the past 12 months.
What is Alumis Inc.’s market cap?
Alumis Inc.’s market cap is $3.71B.
When is Alumis Inc.’s upcoming earnings report date?
Alumis Inc.’s upcoming earnings report date is Mar 25, 2026 which is in 21 days.
How were Alumis Inc.’s earnings last quarter?
Alumis Inc. released its earnings results on Nov 13, 2025. The company reported -$1.06 earnings per share for the quarter, missing the consensus estimate of -$0.932 by -$0.128.
Is Alumis Inc. overvalued?
According to Wall Street analysts Alumis Inc.’s price is currently Undervalued.
Does Alumis Inc. pay dividends?
Alumis Inc. does not currently pay dividends.
What is Alumis Inc.’s EPS estimate?
Alumis Inc.’s EPS estimate is -0.98.
How many shares outstanding does Alumis Inc. have?
Alumis Inc. has 117,506,000 shares outstanding.
What happened to Alumis Inc.’s price movement after its last earnings report?
Alumis Inc. reported an EPS of -$1.06 in its last earnings report, missing expectations of -$0.932. Following the earnings report the stock price went up 4.545%.
Which hedge fund is a major shareholder of Alumis Inc.?
Currently, no hedge funds are holding shares in ALMS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alumis Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$38.38 (29.14% Upside)
$38.38 (29.14% Upside)
Blogger Sentiment
Bearish
ALMS Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 1.8M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $34.9M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▲ 0.3%
Last 30 Days ▼ 1.4%
Last 30 Days ▼ 1.4%
Technicals
SMA
Positive
20 days / 200 days
Momentum
535.76%
12-Months-Change
Fundamentals
Return on Equity
-66.88%
Trailing 12-Months
Asset Growth
18.29%
Trailing 12-Months
Company Description
Alumis Inc.
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. It develops ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis, systemic lupus erythematosus, and non-infectious uveitis; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. The company was incorporated in 2021 and is headquartered in South San Francisco, California.
ALMS Stock 12 Month Forecast
Average Price Target
$38.38
▲(29.14% Upside)
Technical Analysis
Ownership Overview
Currently, No data available
---